New evidence for alpha clustering structure in the ground state band of ²¹²Po

Half-lives of the low-lying yrast states of 212Po have been measured using the delayed coincidence fast-timing method. We report on the first measurement of the 41+ half-life, as well as a new measurement of the 61+ half-life with improved accuracy compared to previous studies. The extracted lifetime of the 41+ and 61+ state have been determined to be 100(14) ps and 1.66(28) ns respectively. With these measurements, precise values are now available for the reduced transition strengths B(E2) of all ground state band levels in 212Po up to the first 8+ state, in particular B(E2; 41+→21+) = 9.4(13) W.u. and B(E2;61+→41+) = 8.7(15) W.u. Comparison of the new available data with an α-clustering model calculation provides evidence that the inclusion of the α-cluster degree of freedom significantly improves agreement with experimental data compared to earlier shell model calculations

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)

The majority of patients with Hodgkin Lymphoma (HL) can be cured with stage and risk adapted treatment today. Therefore, current research focuses on reducing long-term sequelae of treatment. Osteonecrosis (ON) is a severe long-term complication of HL treatment which has so far not been systematically evaluated. Hence, we investigated incidence, risk factors and timing of symptomatic ON in HL patients. Further endpoints included localization, intervention and outcome of ON. We included all qualified HL patients of the randomized German Hodgkin Study Group trials HD10-15 and HD18, recruited between 05/1998 and 07/2014 and aged from 16 to 60 years. Among 11 330 patients, 66 developed symptomatic ON after first-line treatment, 83.3% within three years. The incidence of symptomatic ON was 0.2% in early-stage HL and 1.0% in advanced-stage HL. Logistic regression revealed the total cumulative corticosteroid dose to be a strong risk factor interacting with younger age. Male sex additionally increased the risk of symptomatic ON. The prognostic value of the corresponding logistic regression model was rather high (AUC = 0.78). Other tested potential risk factors including obesity, IPS and radiotherapy did not further increase the risk of ON. Further development of current treatment protocols should aim to reduce the cumulative corticosteroid dose

The GHSG Approach to Treating Hodgkin's Lymphoma

Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients can be cured long term. In refractory or relapsed HL, intensified treatment including high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is associated with progression-free survival (PFS) of 50 %. Evaluation of novel drugs in multiple relapsed or refractory cases, better treatment options for elderly patients and reducing treatment-related side effects are the main focus of current research. Recent clinical developments and future approaches in the treatment of HL will be discussed in this review